Aims: To ascertain the protective role of calcitriol in the development of diabetic nephropathy and unravel the mechanism of the protective effects.
Methods: In this prospective study, 69 patients were screened for type 1 diabetes, and 31 patients with type 1 diabetes were enrolled. Among these 31 patients, 24 patients had insufficient or deficient levels of serum vitamin D and 21 patients complied with calcitriol and were followed up. At baseline, these 21 patients who suffered from vitamin D deficiency or insufficiency displayed elevated inflammation markers and urinary albumin excretion in contrast with patients with sufficient vitamin D. Simultaneously, serum 25(OH)D3 level was negatively associated with serum and urinary inflammation markers, such as TNF-α, IL-6, and ICAM-1. Six months later, even though glycol-metabolism was not alleviated, all the serum and urinary inflammation markers decreased significantly. Meanwhile, proteinuria declined with inflammation markers.
Results: Calcitriol supplementation alleviated inflammation and proteinuria in patients with type 1 diabetes.
Conclusions: Calcitriol might delay the development of diabetic nephropathy through suppressing inflammation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4307500 | PMC |
Publication Analysis
Top Keywords
Similar Publications
The Complex Role of Matrix Metalloproteinase-2 (MMP-2) in Health and Disease.
Int J Mol Sci
December 2024
Pittsburgh Heart, Lung and Blood Vascular Medicine Institute (VMI), University of Pittsburgh School of Medicine, Pittsburgh, PA 15260, USA.
Matrix metalloproteinase-2 (MMP-2), a zinc-dependent enzyme, plays a critical role in the degradation and remodeling of the extracellular matrix (ECM). As a member of the gelatinase subgroup of matrix metalloproteinases, MMP-2 is involved in a variety of physiological processes, including tissue repair, wound healing, angiogenesis, and embryogenesis. It is primarily responsible for the degradation of type IV and V collagen, fibronectin, laminin, and elastin, which are essential components of the ECM.
View Article and Find Full Text PDFSigma-1 Receptor as a Novel Therapeutic Target in Diabetic Kidney Disease.
Int J Mol Sci
December 2024
MTA-SE Lendület "Momentum" Diabetes Research Group, 1083 Budapest, Hungary.
Diabetic kidney disease (DKD) is the leading cause of chronic kidney disease. Current treatments for DKD do not halt renal injury progression, highlighting an urgent need for therapies targeting key disease mechanisms. Our previous studies demonstrated that activating the Sigma-1 receptor (S1R) with fluvoxamine (FLU) protects against acute kidney injury by inhibiting inflammation and ameliorating the effect of hypoxia.
View Article and Find Full Text PDFDiabetic Nephropathy-Associated Impaired Aortic Function Is Not Mediated by Mean Arterial Pressure and Its Determinants.
J Clin Med
December 2024
Cardiovascular Pathophysiology and Genomics Research Unit, School of Physiology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg 2193, South Africa.
The study aimed to assess the potential impacts of mean arterial pressure (MAP) and its determinants (cardiac output and systemic vascular resistance) on diabetic nephropathy (DNP)-associated impaired aortic function. This multi-ethnic study included 115 chronic kidney disease (CKD) patients (67 non-dialysis and 48 dialysis). Six aortic function measures were evaluated by SpygmoCor.
View Article and Find Full Text PDFDulaglutide and Dapagliflozin Combination Concurrently Improves the Endothelial Glycocalyx and Vascular and Myocardial Function in Patients with T2DM and Albuminuria vs. DPP-4i.
J Clin Med
December 2024
2nd Department of Internal Medicine Research Unit and Diabetes Centre, Attikon Hospital, Medical School, National and Kapodistrian University of Athens, Rimini 1 Str., Chaidari, 12462 Athens, Greece.
: The association between diabetic nephropathy and arterial elasticity and endothelial function is well established. In this study, we compared the effect of the combination of dulaglutide and dapagliflozin versus DPP-4 inhibitors on the endothelial glycocalyx, arterial stiffness, myocardial function, and albuminuria. : Overall, 60 patients were randomized to combined dulaglutide and dapagliflozin treatment (n = 30) or DPP-4 inhibitors (DPP-4i, n = 30) (ClinicalTrials.
View Article and Find Full Text PDFComparing Long-Term Outcomes in Glomerular Disease Patients Presenting with Nephrotic Syndrome Versus Nephrotic Range Proteinuria.
Life (Basel)
December 2024
Department of Nephrology, Faculty of Medicine, University of Medicine and Pharmacy "Carol Davila", 050474 Bucharest, Romania.
Background: Despite extensive research on proteinuria's impact on chronic kidney disease progression, there is no direct comparison of outcomes in biopsy-diagnosed glomerular disease (GD) patients with nephrotic syndrome (NS) or nephrotic range proteinuria (NRP). Our study addresses this gap, comparing long-term outcomes between NS and NRP.
Methods: We conducted a retrospective study on 240 kidney biopsy-proven GD patients, tracked from 2010 to 2015 until end-stage kidney disease (ESKD), death, or the study end in January 2022.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!